Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
The company recently received a $52.00M Series A investment on 11 May 2021 led by a group of prominent investors including Two Sigma Ventures, 8VC, WPSS.bio, Freeflow Ventures, Sherpa Healthcare Partners, and Bossanova Investimentos.
Appia Bio operates in the Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries, positioning itself at the forefront of innovative medical advancements and potentially lucrative prospects within the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $52.00M | 6 |
|
11 May 2021 |
No recent news or press coverage available for Appia Bio.
We care about your data, and we'd love to use cookies make your experience better.
